|
|
- 2019
Targeting TMEM176B Enhances Antitumor Immunity and Augments the Efficacy of Immune Checkpoint Blockers by Unleashing Inflammasome ActivationDOI: https://doi.org/10.1016/j.ccell.2019.04.003 Abstract: ？ TMEM176B inhibits the NLRP3 inflammasome by controlling cytosolic Ca2+. ？ Lack of Tmem176b enhances antitumor immunity via the caspase-1/IL-1β pathway ？ Human tumors responding to immune checkpoint blockade display an inflammasome-activated signature ？ A TMEM176B inhibitor improves the antitumor activity of immune checkpoint blockad
|
